Kura Oncology (KURA) Set to Announce Quarterly Earnings on Thursday

Kura Oncology (NASDAQ:KURA) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.64) per share for the quarter.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.04. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.53) earnings per share. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kura Oncology Stock Up 1.6 %

Kura Oncology stock opened at $16.99 on Friday. The company has a market capitalization of $1.30 billion, a P/E ratio of -7.50 and a beta of 0.84. Kura Oncology has a 1-year low of $7.98 and a 1-year high of $24.17. The firm’s fifty day simple moving average is $19.18 and its 200-day simple moving average is $20.03. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02.

Analysts Set New Price Targets

KURA has been the subject of several recent research reports. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and cut their target price for the company from $26.00 to $19.00 in a research note on Monday, October 14th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Thursday, October 24th. Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Friday, August 9th. Finally, UBS Group began coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.